Apixaban Safety and Therapy Adherence in Patients With Atrial Fibrillation

Inclusion criteria

• Patients over 18 years of age.
• Hemodynamically stable patients.
• Patients with non-valvular atrial fibrillation.
• Patients in whom the investigator, based on clinical assessment makes a decision to introduce apixaban therapy.
• Patients who are on apixaban therapy for the first time

Exclusion criteria

• Positive history of angioneurotic edema.
• Active, clinically significant bleeding.
• Congenital or acquired bleeding disorder.
• The presence of a malignant tumor.
• Current or recent presence of gastrointestinal ulcer.
• The presence of established or suspected esophageal varices.
• Positive history of arteriovenous malformations, vascular aneurysms or intraspinal and intracerebral vascular anomalies.
• Patients with artificial heart valves.
• Liver cirrhosis and active liver disease associated with coagulopathy and clinically significant risk of bleeding.
• Dialysis patients (GFR <15 ml/min).
• Simultaneous use of other anticoagulants.
• Pregnancy and breastfeeding.
• Patients who previously used apixaban in therapy.

Withdrawal Criteria:

• Deterioration of the clinical picture of the underlying disease that requires discontinuation of investigational therapy.
• Development of serious adverse events that require discontinuation of therapy.
• Occurrence of pregnancy.
• Development of another disease that affects the course of research.